Shanghai Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 5.147 billion yuan, a year-on-year increase of 26.96%
Shanghai Pharma released its third-quarter report for 2025, achieving operating revenue of 215.072 billion yuan from January to September 2025, a year-on-year increase of 2.60%. The net profit attributable to the parent company was 5.147 billion yuan, a year-on-year increase of 26.96%. The sales revenue of the pharmaceutical industry was 18.164 billion yuan, a year-on-year decrease of 0.66%; the sales revenue of the pharmaceutical business was 196.908 billion yuan, a year-on-year increase of 2.91%. After deducting one-time special gains and losses, the net profit attributable to the parent company was 3.979 billion yuan, a year-on-year decrease of 1.85%. The net cash flow from operating activities was 2.350 billion yuan, continuing to maintain high-quality development
According to the Zhitong Finance APP, Shanghai Pharma (02607) released its third-quarter report for 2025. From January to September 2025, the company achieved operating revenue of RMB 215.072 billion, a year-on-year increase of 2.60%. Among them, the pharmaceutical manufacturing segment achieved sales revenue of RMB 18.164 billion, a year-on-year decrease of 0.66%; the pharmaceutical commerce segment achieved sales revenue of RMB 196.908 billion, a year-on-year increase of 2.91%. The company achieved a net profit attributable to shareholders of the listed company of RMB 5.147 billion (of which: the industrial segment contributed RMB 1.665 billion, the commercial segment contributed RMB 2.653 billion, and the main equity investees contributed RMB 324 million), a year-on-year increase of 26.96%. This was mainly due to a one-time special gain resulting from the change in accounting for Hutchison Whampoa from the equity method of accounting for joint ventures to subsidiary accounting. After deducting the aforementioned one-time special gains and losses, the net profit attributable to the parent company was RMB 3.979 billion, a year-on-year decrease of 1.85%. The company's net cash flow from operating activities was RMB 2.350 billion, continuing to maintain high-quality development
